Otcqb Podcast

Wize Pharma (OTCQB: WIZPD) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize Pharma has inlicensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of Dry Eye Syndrome, and other ophthalmological illnesses, including Sjorgen's Syndrome and Conjunctivochalasis.